Chikungunya - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Chikungunya - Pipeline Review, H1 2016', provides an overview of the Chikungunya pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chikungunya, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chikungunya - The report reviews pipeline therapeutics for Chikungunya by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chikungunya therapeutics and enlists all their major and minor projects - The report assesses Chikungunya therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chikungunya Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chikungunya - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chikungunya Overview 10 Therapeutics Development 11 Pipeline Products for Chikungunya - Overview 11 Pipeline Products for Chikungunya - Comparative Analysis 12 Chikungunya - Therapeutics under Development by Companies 13 Chikungunya - Therapeutics under Investigation by Universities/Institutes 15 Chikungunya - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Chikungunya - Products under Development by Companies 18 Chikungunya - Products under Investigation by Universities/Institutes 19 Chikungunya - Companies Involved in Therapeutics Development 20 Abivax S.A. 20 Arbovax, Inc. 21 Arno Therapeutics, Inc. 22 Bharat Biotech International Limited 23 Etubics Corporation 24 Indian Immunologicals Limited 25 Inovio Pharmaceuticals, Inc. 26 Integral Molecular, Inc. 27 Integrated BioTherapeutics, Inc. 28 Merck & Co., Inc. 29 Nanotherapeutics, Inc. 30 PaxVax, Inc. 31 Profectus BioSciences, Inc. 32 Takeda Pharmaceutical Company Limited 33 Themis Bioscience GmbH 34 Valneva SE 35 Chikungunya - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 ABX-309 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Antibody for Chikungunya - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 AR-12 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 chikungunya (viral like particles) vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 chikungunya vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 chikungunya vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 chikungunya vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 chikungunya vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 chikungunya vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 chikungunya vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 chikungunya vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 chikungunya vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 chikungunya vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 chikungunya vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 chikungunya vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 chikungunya vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 chikungunya vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 chikungunya vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 chikungunya vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 DEF-201 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 IMCKV-063 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Monoclonal Antibodies for Chikungunya - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Monoclonal Antibody for Chikungunya - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 MV-CHIK - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Chikungunya - Recent Pipeline Updates 76 Chikungunya - Dormant Projects 80 Chikungunya - Product Development Milestones 81 Featured News & Press Releases 81 Mar 22, 2016: Inovio's DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study 81 Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 82 Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 84 Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 84 Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1 85 Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 86 Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 87 Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 87 Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 88 Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 88 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List of Tables
Number of Products under Development for Chikungunya, H1 2016 11 Number of Products under Development for Chikungunya - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Chikungunya - Pipeline by Abivax S.A., H1 2016 20 Chikungunya - Pipeline by Arbovax, Inc., H1 2016 21 Chikungunya - Pipeline by Arno Therapeutics, Inc., H1 2016 22 Chikungunya - Pipeline by Bharat Biotech International Limited, H1 2016 23 Chikungunya - Pipeline by Etubics Corporation, H1 2016 24 Chikungunya - Pipeline by Indian Immunologicals Limited, H1 2016 25 Chikungunya - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 26 Chikungunya - Pipeline by Integral Molecular, Inc., H1 2016 27 Chikungunya - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 28 Chikungunya - Pipeline by Merck & Co., Inc., H1 2016 29 Chikungunya - Pipeline by Nanotherapeutics, Inc., H1 2016 30 Chikungunya - Pipeline by PaxVax, Inc., H1 2016 31 Chikungunya - Pipeline by Profectus BioSciences, Inc., H1 2016 32 Chikungunya - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 33 Chikungunya - Pipeline by Themis Bioscience GmbH, H1 2016 34 Chikungunya - Pipeline by Valneva SE, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Chikungunya Therapeutics - Recent Pipeline Updates, H1 2016 76 Chikungunya - Dormant Projects, H1 2016 80
List of Figures
Number of Products under Development for Chikungunya, H1 2016 11 Number of Products under Development for Chikungunya - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Top 10 Targets, H1 2016 37 Number of Products by Stage and Top 10 Targets, H1 2016 37 Number of Products by Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Routes of Administration, H1 2016 41 Number of Products by Stage and Routes of Administration, H1 2016 41 Number of Products by Top 10 Molecule Types, H1 2016 43 Number of Products by Stage and Top 10 Molecule Types, H1 2016 43
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.